Disease | hyperthermia |
Comorbidity | C0302592|cervical carcinoma |
Sentences | 1 |
PubMedID- 25660155 | Conclusion: it is not feasible to combine lapatinib with fixed doses of cisplatin and hyperthermia in patients with recurrent cervical carcinoma in a previously irradiated area mainly because of increased cisplatin-related toxicity. |
Page: 1